Merdury Biopharmaceutical

Merdury Biopharmaceutical R&D per Employee

The R&D Spending per Employee of Merdury Biopharmaceutical (6932.TWO) as of Oct 18, 2026 is 3.40 M TWD. In the previous year, R&D Spending per Employee was 2.51 M TWD — a change of 35.29% (higher).

R&D per Employee

3.40 MTWD

YoY

35.29%

Last updated:

R&D Spending per Employee of Merdury Biopharmaceutical is 2025 3.40 M TWD. R&D Spending per Employee of Merdury Biopharmaceutical was 2024 2.51 M TWD. It decreases by 35.29% higher compared to the previous year.

The Merdury Biopharmaceutical R&D per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D per Employee
Date
R&D per Employee
Jan 1, 2021
216,692.31 TWD
Jan 1, 2022
1.19 M TWD
Jan 1, 2023
1.64 M TWD
Jan 1, 2024
2.51 M TWD
Jan 1, 2025
3.40 M TWD
The Merdury Biopharmaceutical R&D per Employee history
YEARR&D per EmployeeYoY
3.40 MTWD+35.29%
2.51 MTWD+52.82%
1.64 MTWD+38.66%
1.19 MTWD+447.04%
216,692.31TWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Merdury Biopharmaceutical Stock analysis

What does Merdury Biopharmaceutical do? Merdury Biopharmaceutical Corp is a pharmaceutical company based in Taipei, Taiwan, operating within the Health Care sector. The company has a small workforce of 13 employees and went public on December 23, 2022, with its ticker listed as 6932.TWO. Merdury Biopharmaceutical Corp focuses on developing drugs that address unmet medical needs, difficult generic drugs, and second-class new drugs. The company utilizes a self-developed drug development platform called StackDose, which enables the creation of tablets with controlled dissolution properties, allowing for either immediate or sustained drug release. This technology supports the development of products such as Sildenafil, Metformin, Tadalafil, Zolpidem, angina treatments, migraine medications, and multi-ingredient antihypertensive drugs. These products are primarily marketed and sold in Taiwan and the United States. The company's website is https://merdury.com, providing further information about its operations and offerings. Merdury Biopharmaceutical Corp operates as a publicly traded entity with a focus on innovative pharmaceutical solutions within the Taiwanese and U.S. markets. Merdury Biopharmaceutical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Merdury Biopharmaceutical stock

R&D Spending per Employee of Merdury Biopharmaceutical is 3.40 M TWD in 2025.

R&D Spending per Employee of Merdury Biopharmaceutical changed from 2.51 M TWD to 3.40 M TWD, representing a 35.29% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of R&D Spending per Employee Merdury Biopharmaceutical since 2006 – with annual values, charts, and detailed analysis.

R&D per employee shows the research and development investment allocated per employee. Higher values indicate innovation-focused companies.

R&D Spending per Employee's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track R&D Spending per Employee's Merdury Biopharmaceutical historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Workforce — Merdury Biopharmaceutical

EmployeesRevenue per EmployeeProfit per EmployeeMarket Cap per EmployeeEBIT per EmployeeEBITDA per EmployeeR&D per EmployeePP&E per Employee

All Key Metrics — Merdury Biopharmaceutical